ISR - Immune System Regulation Holding AB (publ.) 2[nd] half of 2021, including year-end report is now published on the website: www.israb.se
“2021 has been a very eventful year, where ISR has been moving at high speed in the development of our full-spike dry powder COVID vaccine for nasal administration, which has also led ISR as a company to quickly develop and adapt to requirements to ensure reaching our set goals. In 2022, we expect to drive a fast, efficient and successful clinical process for future regulatory marketing approval for ISR52 as primary vaccination in COVID, in parallel with continued development of other projects and intensified partner discussions for commercialization” Ola Winqvist, CEO of ISRSignificant